B
L. E. Bermudez and Inderlied, C. B.,
“Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.”,
Microbial drug resistance (Larchmont, N.Y.), vol. 3, no. 3, pp. 277-82, 1997.
L. E. Bermudez, Young, L. S., and Enkel, H.,
“Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins.”,
Infection and immunity, vol. 59, no. 5, pp. 1697-702, 1991.
L. E. Bermudez, Wagner, D., and Sosnowska, D.,
“Mechanisms of Mycobacterium avium pathogenesis.”,
Archivum immunologiae et therapiae experimentalis, vol. 48, no. 6, pp. 521-7, 2000.
L. E. Bermudez, Kemper, C. A., and Deresinski, S. C.,
“Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF.”,
Biotherapy (Dordrecht, Netherlands), vol. 8, no. 2, pp. 135-42, 1994.
L. E. Bermudez, Petrofsky, M., and Stevens, P.,
“Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.”,
Immunology, vol. 94, no. 3, pp. 297-303, 1998.
L. E. Bermudez, Wu, M., Young, L. S., and Inderlied, C. B.,
“Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.”,
The Journal of infectious diseases, vol. 166, no. 4, pp. 923-6, 1992.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor.”,
Lymphokine research, vol. 9, no. 2, pp. 137-45, 1990.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Chee, C. B., Aralar, P., Petrofsky, M., Parman, T., Green, C. E., Lewin, A. H., Ellis, W. Y., and Young, L. S.,
“Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice.”,
Antimicrobial agents and chemotherapy, vol. 56, no. 8, pp. 4202-6, 2012.
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S.,
“Naturally occurring antibodies against Mycobacterium avium complex.”,
Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, Sangari, F. J., Kolonoski, P., Petrofsky, M., and Goodman, J.,
“The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells.”,
Infection and immunity, vol. 70, no. 1, pp. 140-6, 2002.
L. E. Bermudez, Young, L. S., and Inderlied, C. B.,
“Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.
L. E. Bermudez, Shelton, K., and Young, L. S.,
“Comparison of the ability of Mycobacterium avium, M. smegmatis and M. tuberculosis to invade and replicate within HEp-2 epithelial cells.”,
Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, vol. 76, no. 3, pp. 240-7, 1995.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S.,
“SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.”,
Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.”,
The Journal of infectious diseases, vol. 156, no. 3, pp. 510-3, 1987.